DHNP-2205

DHNP-2205 is an investigational small molecule drug candidate developed by the South Korean pharmaceutical company Daehan Nupharm. It is specifically designed to treat gonadotropin-related conditions, a category that typically encompasses hormone-dependent disorders such as endometriosis and uterine fibroids (leiomyoma). While detailed clinical data is limited, the drug is categorized as a synthetic small molecule intended to modulate the endocrine axis, likely by acting as a gonadotropin-releasing hormone (GnRH) receptor antagonist. By targeting this pathway, DHNP-2205 aims to suppress the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing the levels of ovarian steroids like estrogen that drive the progression of these conditions.